Vasoconstrictor potency of fixed combination calcipotriol plus betamethasone dipropionate foam versus other corticosteroid psoriasis treatments

Introduction

- Many topical corticosteroids (CS) of differing potencies and formulations are available for treating psoriasis vulgaris
- Topical CS potency can be assessed by the vasoconstriction assay (McKenzie-Stoughton), which is based on the blanching response of skin induced by topical CS application on healthy skin¹
- This assay is recommended for topical CS potency ranking based on a correlation with clinical efficacy in psoriasis
- A foam formulation of fixed-dose combination calcipotriol $50 \,\mu\text{g/g}$ (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed as a treatment option for patients with psoriasis
- Clinical studies have demonstrated greater efficacy with Cal/BD foam versus the gel and ointment formulations²⁻⁶
- The objective of this study was to compare the CS potency of BD in Cal/BD foam with existing CS-containing topical products

Methods

PATIENTS

- The study enrolled healthy, non-smoking volunteers aged 18–50 years
- All subjects were required to demonstrate adequate vasoconstriction prior to the study, defined as a visual skin blanching score of at least one unit following non-occlusive BD 0.05% ointment application for 4–6 hours
- Subjects were excluded if they received systemic treatments or any medications that could interfere with the blanching reaction within 2 weeks, or had used topical CS on the test sites within 4 weeks prior to enrolment

STUDY DESIGN

- This was a Phase I, single-centre, investigator-blinded, vehicle-controlled, intra-individual comparison study (NCT02973776)
- Each volunteer received a single application, under non-occlusive conditions of: Cal/BD foam, clobetasol propionate 0.05% cream (CP; very potent), BD 0.05% ointment (potent), mometasone furoate 0.1% cream (MF; potent), hydrocortisone-17-butyrate 0.1% ointment (HB; moderately potent) and foam vehicle to six circular test sites (each 2.2 cm in diameter) on the anterior forearms
- After 16 hours of exposure, any remaining product was removed

ST
•
•

	Subjects (n=36)		
Median age (range), years	34.5 (19–50)		
Males:Females, n (%)	14:22 (38.9:61.1)		
Race, n (%)			
White	36 (100.0)		
Fitzpatrick skin type, n (%)			
II	5 (13.9)		
III	30 (83.3)		
IV	1 (2.8)		
Median BMI (range), kg/m²	22.9 (16.2–34.5)		
BMI, body mass index			

Catherine Queille-Roussel,¹ Jakob Nielsen² ¹Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France; ²LEO Pharma A/S, Ballerup, Denmark

UDY OBJECTIVES AND ASSESSMENTS

The primary objective was to compare the vasoconstriction potential of Cal/BD foam with the other treatments using the human skin blanching test (McKenzie-Stoughton vasoconstriction assay)¹

Skin blanching for each treatment was assessed 2 hours after the 16-hour application period by two independent, trained observers

 Visual assessment of skin blanching was scored on a 9-point scale from 0-4 (0 = no change, 4 = maximal blanching; half-point scores were used for intermediate changes)

Local tolerability was assessed at the same time as skin blanching and at follow-up; safety was assessed throughout the study by evaluation of adverse events (AEs)

STATISTICAL ANALYSIS

The mean of the two individual skin blanching visual scores were calculated for each treatment, and non-parametric tests were performed. Kruskal-Wallis test for the overall effect, and Wilcoxon Signed Rank test for the pairwise comparisons (Cal/BD foam vs other treatments)

Results

PATIENTS

• A total of 36 healthy volunteers were randomized and analysed (Table 1)

Table 2. Baseline demographic and characteristics of randomized subjects




Figure 1. Box plot showing visual assessment of skin blanching 2 hours after 16 hours of treatment application

The horizontal line represents the median, and the circle represents the mean; the box represents the interquartile range (IQR), and the whiskers represent the range within 1.5 x IQR

Table 2. Skin blanching scores by treatment, assessed 2 hours after 16 hours of treatment application

Treatmer

Cal/BD foa

CP cream

BD ointme

MF cream

HB ointme

Foam vehi

SD, standard deviation

ASSESSMENT OF SKIN BLANCHING

• All active treatments resulted in greater skin blanching compared with foam vehicle (Figure 1; Table 2)

t	Mean (SD)	Median (range)	<i>P</i> value (v Cal/BD foam)
am	1.93 (0.56)	2.00 (0.75–3.00)	—
	3.09 (0.55)	3.00 (1.75–4.00)	<0.001
ent	1.85 (0.59)	1.75 (0.75–3.00)	0.30
l	2.11 (0.59)	2.00 (1.00–3.75)	0.22
ent	1.40 (0.66)	1.25 (0.50–3.00)	<0.001
icle	0.06 (0.13)	0 (0–0.50)	<0.001

- for both) [Figure 1; Table 2]
- of 0 (ie, no reaction)

Conclusions

- into the skin
- **CP cream**



References

- 1. McKenzie AW & Stoughton RB. Arch Dermatol 1962;86:608–10
- 2. Leonardi C et al. J Drugs Dermatol 2015;14:1468–77
- 3. Koo J et al. J Dermatolog Treat 2016;27:120–7
- 4. Paul C et al. J Eur Acad Dermatol Venereol 2017;31:119–26
- 5. Queille-Roussel C et al. Clin Drug Investig 2015;35:239–45
- 6. Stein GL et al. J Drugs Dermatol 2016;15:951–7
- 7. Queille-Roussel C et al. J Eur Acad Dermatol Venereol 2016;30:1951–6

P1908

 Skin blanching with Cal/BD foam was significantly lower than with CP cream (P<0.001), similar to BD ointment and MF cream, and significantly higher than HB ointment and foam vehicle (P<0.001

No AEs were reported, and all subjects had a local tolerability score

Understanding topical CS potency is important to ensure the appropriate use of treatments for psoriasis:

 The degree of skin blanching is used as a measure of the inherent potency of a CS, and its ability to diffuse

This study showed that, consistent with CS potency classifications, the steroid potency of Cal/BD foam was similar to BD ointment and MF cream, significantly stronger than that of HB ointment, but weaker than that of very potent

 These findings expand on those from a previously reported Phase I study, which showed that Cal/BD foam was a more potent formulation than Cal/BD ointment⁷

Acknowledgements

 This study was sponsored by LEO Pharma. Medical writing support was provided by Andrew Jones, PhD, from Mudskipper Business Limited, funded by LEO Pharma